Clincosm LogoSign in Get a demo

PINPOINT: Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy

Sponsor
Rutgers, The State University of New Jersey (Other)
Overall Status
Recruiting
CT.gov ID
NCT05034289
Collaborator
American Cancer Society, Inc. (Other), Pfizer (Industry)
116
Enrollment
1
Location
21.4
Anticipated Duration (Months)
5.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the research is to: develop an educational website to empower Black and African American cancer patients to make informed decisions about personalized cancer treatment and clinical trials.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The website offers tools for discussing innovative treatments with their clinicians, finding clinical trials, and locating support groups. We are conducting key informant interviews, testing the website with pilot tester and asking volunteers from our Community Advisory Board to review our website prototype to further improve its design and features.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    116 participants
    Observational Model:
    Other
    Time Perspective:
    Other
    Official Title:
    Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy
    Actual Study Start Date :
    Dec 2, 2020
    Anticipated Primary Completion Date :
    Sep 1, 2022
    Anticipated Study Completion Date :
    Sep 15, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Community Advisory Board, Key Informants and Pilot Testers [June 2021-June 2022]

      Employ a community-engaged approach, including a Community Advisory Board and key informant interviews, to a) assess knowledge, attitudes, beliefs, and sociocultural, clinical, and system-level factors (e.g., barriers) that may explain disparities in decisions about use of precision oncology in Black cancer patients

    2. Website Development [June 2021-June 2023]

      Utilize this information to guide the iterative development and pilot testing of an innovative, patient-centered and culturally tailored internet-based education and decision support intervention, "Promoting INformed approaches in Precision Oncology and ImmuNoTherapy (PINPOINT)," to reduce racial disparities in access to and use of guideline-based therapy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria for Patient Key Informant:

    • Age 18 and older

    • Self-identify as Black/African American

    • Diagnosed with solid tumor

    • Able to read and speak English fluently

    • Able to provide electronic informed consent

    • Able to complete 2 surveys and an in-depth interview

    Inclusion Criteria for Relative Key Informant:

    • Age 18 and older

    • Spouse, blood relative, or caregiver of a cancer patient who identifies as Black/African American

    • Able to read and speak English fluently

    • Able to provide electronic informed consent

    • Able to complete 2 surveys and an in-depth interview

    Inclusion Criteria for Provider Key Informant:

    • Age 18 and older

    • Physician, nurse, social worker, patient navigator, or financial counselor

    • Work in oncology setting

    • Able to read and speak English fluently

    • Able to provide electronic informed consent

    • Able to complete 1 survey and an in-depth interview

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Rutgers Cancer Institute of New Jersey New Brunswick New Jersey United States 08901

    Sponsors and Collaborators

    • Rutgers, The State University of New Jersey
    • American Cancer Society, Inc.
    • Pfizer

    Investigators

    • Principal Investigator: Anita Y Kinney, PhD, RN, Rutgers Cancer Institute of New Jersey

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anita Y. Kinney, PhD, RN, Study Principal Investigator; Associate Director for Cancer Health Equity, Rutgers, The State University of New Jersey
    ClinicalTrials.gov Identifier:
    NCT05034289
    Other Study ID Numbers:
    • Pro2021000072
    First Posted:
    Sep 5, 2021
    Last Update Posted:
    Aug 5, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Aug 5, 2022